Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C20H30O
CAS Number:
Molecular Weight:
286.45
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
403040
eCl@ss:
34058018
grade
reference material
Quality Level
form
liquid
feature
(Snap-N-Shoot®), (Snap-N-Spike®)
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
100 μg/mL ± 25% (Refer to COA) (Ethanol with 0.1% (w/v) BHT)
application(s)
clinical testing
format
single component solution
storage temp.
−70°C
SMILES string
CC(=C/CO)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C
InChI
1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+
InChI key
FPIPGXGPPPQFEQ-OVSJKPMPSA-N
Features and Benefits
- Fully characterized under ISO/IEC 17025 and ISO 17034 accreditation
- Accompanied with a comprehensive Certificate of Analysis (CoA) with data on stability, homogeneity, accuracy of concentration, uncertainty, and traceability
- Rigorously tested through real-time stability studies to ensure accuracy and shelf life
- Gravimetrically prepared using qualified precision balances to ensure minimal uncertainty
- Flame sealed under argon into ampoules for long-term shelf life
- Offered in a convenient, DEA-exempt format to improve laboratory efficiency
Legal Information
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Flam. Liq. 2
Storage Class
3 - Flammable liquids
wgk
WGK 1
flash_point_f
57.2 °F
flash_point_c
14.0 °C
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Sarmila Mazumder et al.
Lancet (London, England), 385(9975), 1333-1342 (2014-12-17)
Vitamin A supplementation in children aged 6 months to 5 years has been shown to reduce mortality. The efficacy of neonatal supplementation with vitamin A to reduce mortality in the first 6 months of life is plausible but not established.
Gretchen A Stevens et al.
The Lancet. Global health, 3(9), e528-e536 (2015-08-16)
Vitamin A deficiency is a risk factor for blindness and for mortality from measles and diarrhoea in children aged 6-59 months. We aimed to estimate trends in the prevalence of vitamin A deficiency between 1991 and 2013 and its mortality
Malay Rana et al.
Journal of clinical pathology, 67(7), 605-608 (2014-04-09)
Determine the prevalence of fat-soluble vitamin deficiency in children with cystic fibrosis (CF) aged ≤18 years in New South Wales (NSW), Australia, from 2007 to 2010. A retrospective analysis of fat-soluble vitamin levels in children aged ≤18 years who lived in NSW

